{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:30:29Z","timestamp":1778880629640,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Cancer Institute (WIA) funds"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.leukres.2019.106188","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:09:42Z","timestamp":1562843382000},"page":"106188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed\/refractory hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"84","author":[{"given":"Prasanth","family":"Ganesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-7470","authenticated-orcid":false,"given":"Nikita","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana","family":"Joel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manikandan","family":"Dhanushkodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayachandran","family":"Perumal Kalayarasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnarathinam","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trivadi S","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenali Gnana","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January 3","key":"10.1016\/j.leukres.2019.106188_bib0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"April 16","key":"10.1016\/j.leukres.2019.106188_bib0010","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"issue":"March 6","key":"10.1016\/j.leukres.2019.106188_bib0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","article-title":"High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging","volume":"148","author":"Moskowitz","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"December 23","key":"10.1016\/j.leukres.2019.106188_bib0020","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"January 2","key":"10.1016\/j.leukres.2019.106188_bib0025","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2005-11-006957","article-title":"Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma","volume":"109","author":"Schot","year":"2007","journal-title":"Blood."},{"issue":"October 10","key":"10.1016\/j.leukres.2019.106188_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/2040620717728000","article-title":"Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma","volume":"8","author":"Nikolaenko","year":"2017","journal-title":"Ther. Adv. Hematol."},{"issue":"November 31","key":"10.1016\/j.leukres.2019.106188_bib0035","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"June 6","key":"10.1016\/j.leukres.2019.106188_bib0040","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"January 1","key":"10.1016\/j.leukres.2019.106188_bib0045","first-page":"10","article-title":"GDP versus ESHAP regimen in relapsed and\/or refractory hodgkin lymphoma: a comparison study","volume":"9","author":"Ramzi","year":"2015","journal-title":"Int. J. Hematol-Oncol. Stem Cell Res."},{"issue":"January 1","key":"10.1016\/j.leukres.2019.106188_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"December 12","key":"10.1016\/j.leukres.2019.106188_bib0055","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"March 1","key":"10.1016\/j.leukres.2019.106188_bib0060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12032-012-0350-5","article-title":"Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin\u2019s lymphoma and aggressive non-Hodgkin\u2019s lymphoma","volume":"30","author":"Bai","year":"2013","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"issue":"August 8","key":"10.1016\/j.leukres.2019.106188_bib0065","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00277-015-2362-7","article-title":"Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children","volume":"94","author":"Jaffray","year":"2015","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2019.106188_bib0070","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood."},{"issue":"December 23","key":"10.1016\/j.leukres.2019.106188_bib0075","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"issue":"March 3","key":"10.1016\/j.leukres.2019.106188_bib0080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12185-015-1927-5","article-title":"LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy","volume":"103","author":"Khattry","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"September 9","key":"10.1016\/j.leukres.2019.106188_bib0085","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","article-title":"A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi","volume":"24","author":"Olivieri","year":"2018","journal-title":"Biol. Blood Marrow Transplant J. Am. Soc. Blood Marrow Transplant"},{"issue":"December 21","key":"10.1016\/j.leukres.2019.106188_bib0090","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood.V124.21.3984.3984","article-title":"Outpatient administration of high dose BEAM chemotherapy As conditioning for autologous stem cell transplantation for lymphoma results in fewer infectious complications and improved survival","volume":"124","author":"Reid","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106188_bib0095","series-title":"Lomustine, cytarabine, cyclophosphamide, etoposide \u2013 An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors [Internet]","author":"Gupta","year":"2018"},{"issue":"January 1","key":"10.1016\/j.leukres.2019.106188_bib0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.bmt.1705544","article-title":"LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin\u2019s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre","volume":"39","author":"Perz","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"September 27","key":"10.1016\/j.leukres.2019.106188_bib0105","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"September 5","key":"10.1016\/j.leukres.2019.106188_bib0110","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ki.2008.217","article-title":"The analysis of survival data: the Kaplan\u2013meier method","volume":"74","author":"Jager","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.leukres.2019.106188_bib0115","doi-asserted-by":"crossref","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [cited 2018 May 12]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm.","DOI":"10.1016\/B978-0-323-40067-1.00037-1"},{"issue":"June 6","key":"10.1016\/j.leukres.2019.106188_bib0120","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdv077","article-title":"Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin\u2019s lymphoma","volume":"26","author":"Ganesan","year":"2015","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"issue":"June 12","key":"10.1016\/j.leukres.2019.106188_bib0125","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood-2004-12-4750","article-title":"From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential","volume":"105","author":"Re","year":"2005","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261930133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:44Z","timestamp":1758934784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261930133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"alternative-id":["S014521261930133X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106188","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed\/refractory hodgkin\u2019s lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106188"}}